Guangdong Jiaying Pharmaceutical Co., Ltd (SHE:002198)
China · Delayed Price · Currency is CNY 5.55
-0.29 (-4.97%)
May 6, 2026, 3:04 PM CST
SHE:002198 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 385.04 | 383.75 | 375.41 | 533.03 | 659.03 | 574.28 |
Other Revenue | - | - | 0.76 | 0.2 | 0.17 | 0.44 |
| 385.04 | 383.75 | 376.17 | 533.23 | 659.2 | 574.71 | |
Revenue Growth (YoY) | -4.55% | 2.02% | -29.45% | -19.11% | 14.70% | 5.50% |
Cost of Revenue | 179.87 | 153.73 | 151.91 | 186.34 | 229.22 | 143.26 |
Gross Profit | 205.17 | 230.02 | 224.25 | 346.9 | 429.98 | 431.45 |
Selling, General & Admin | 150.06 | 169.81 | 185.89 | 292.82 | 351.17 | 379.1 |
Research & Development | 10.46 | 9.04 | 6.76 | 10.1 | 15.34 | 14.4 |
Other Operating Expenses | 6.12 | 6.49 | 7.19 | 9.07 | 10.59 | 10.67 |
Operating Expenses | 166.64 | 185.34 | 203.88 | 311.34 | 379.76 | 402.16 |
Operating Income | 38.53 | 44.68 | 20.37 | 35.56 | 50.22 | 29.29 |
Interest Expense | - | - | -0 | -0 | -0.45 | -1.02 |
Interest & Investment Income | 0.21 | - | 2.08 | 2.7 | 2.74 | 3.67 |
Other Non Operating Income (Expenses) | -1.5 | -1.28 | -0.02 | 0.01 | -0 | 1.48 |
EBT Excluding Unusual Items | 37.25 | 43.4 | 22.44 | 38.27 | 52.5 | 33.42 |
Gain (Loss) on Sale of Investments | -1.62 | -1.51 | - | 0.53 | 0.26 | -28.8 |
Gain (Loss) on Sale of Assets | -0.13 | -0.13 | 1.61 | 0.14 | -0.01 | -0.19 |
Asset Writedown | -3.8 | -3.8 | - | - | - | -0.01 |
Other Unusual Items | - | - | 1.05 | 0.44 | -1.65 | 1.39 |
Pretax Income | 31.69 | 37.95 | 25.1 | 39.37 | 51.1 | 5.82 |
Income Tax Expense | 4.16 | 7.47 | 4.48 | 5.05 | 7.16 | 4.35 |
Net Income | 27.53 | 30.48 | 20.61 | 34.32 | 43.93 | 1.48 |
Net Income to Common | 27.53 | 30.48 | 20.61 | 34.32 | 43.93 | 1.48 |
Net Income Growth | -10.71% | 47.87% | -39.94% | -21.88% | 2874.04% | -92.55% |
Shares Outstanding (Basic) | 539 | 507 | 508 | 508 | 507 | 509 |
Shares Outstanding (Diluted) | 539 | 507 | 508 | 508 | 507 | 509 |
Shares Change (YoY) | 6.15% | -0.11% | -0.00% | 0.07% | -0.41% | 0.40% |
EPS (Basic) | 0.05 | 0.06 | 0.04 | 0.07 | 0.09 | 0.00 |
EPS (Diluted) | 0.05 | 0.06 | 0.04 | 0.07 | 0.09 | 0.00 |
EPS Growth | -15.88% | 48.03% | -39.94% | -21.94% | 2886.21% | -92.58% |
Free Cash Flow | -125.12 | -100.92 | 22.14 | 93.39 | 24.41 | 49.46 |
Free Cash Flow Per Share | -0.23 | -0.20 | 0.04 | 0.18 | 0.05 | 0.10 |
Dividend Per Share | - | - | - | 0.050 | - | - |
Gross Margin | 53.29% | 59.94% | 59.61% | 65.05% | 65.23% | 75.07% |
Operating Margin | 10.01% | 11.64% | 5.42% | 6.67% | 7.62% | 5.10% |
Profit Margin | 7.15% | 7.94% | 5.48% | 6.44% | 6.67% | 0.26% |
Free Cash Flow Margin | -32.50% | -26.30% | 5.89% | 17.51% | 3.70% | 8.61% |
EBITDA | 60.25 | 65.97 | 39.92 | 59.77 | 76.11 | 57.69 |
EBITDA Margin | 15.65% | 17.19% | 10.61% | 11.21% | 11.55% | 10.04% |
D&A For EBITDA | 21.72 | 21.29 | 19.55 | 24.21 | 25.89 | 28.4 |
EBIT | 38.53 | 44.68 | 20.37 | 35.56 | 50.22 | 29.29 |
EBIT Margin | 10.01% | 11.64% | 5.42% | 6.67% | 7.62% | 5.10% |
Effective Tax Rate | 13.11% | 19.69% | 17.87% | 12.83% | 14.02% | 74.63% |
Revenue as Reported | - | - | 376.17 | 533.23 | 659.2 | 574.71 |
Advertising Expenses | - | - | 59.46 | 52.85 | 63.8 | 59.47 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.